FDA Grants Fast Track Designation to BNT113 mRNA Immunotherapy for HPV16-Positive Head and Neck Cancer
核心洞察
The FDA has granted fast track designation to BNT113, an investigational mRNA cancer immunotherapy, for treating patients with HPV16-positive head and neck squamous cell carcinoma expressing PD-L1 (搜索).
The designation was based on preliminary data from the ongoing phase 2/3 AHEAD-MERIT trial, which showed a 40% objective response rate when BNT113 was combined with pembrolizumab.
BNT113 encodes HPV16 E6 and E7 proteins to induce specific antitumor immune responses, addressing an unmet medical need as no HPV-targeted treatments are currently approved for this indication.
The FDA has granted fast track designation to BNT113, an investigational mRNA cancer immunotherapy developed by BioNTech, for the treatment of patients with human papillomavirus type 16 positive (HPV16+) head and neck squamous cell carcinoma (HNSCC) expressing PD-L1 (搜索). The decision was based on preliminary safety and efficacy data from the ongoing phase 2/3 AHEAD-MERIT trial.
Clinical Trial Results Drive Regulatory Decision
The AHEAD-MERIT trial evaluated BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as first-line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing PD-L1 (搜索) with a combined positive score of 1 or higher.
Among 15 patients treated with at least one dose of BNT113, the combination demonstrated promising clinical activity. Four patients experienced a complete response and two experienced a partial response as best response, yielding an unconfirmed objective response rate of 40% per blinded independent committee review. The unconfirmed disease control rate per BICR was 53.3%, with an investigator-assessed unconfirmed ORR of 33.3% and DCR of 60.0%.
The median progression-free survival per BICR was 3.9 months (95% CI, 2.1-10.6), with 6-, 12-, and 18-month rates of 42.3%, 14.1%, and 14.1%, respectively. Per investigator assessment, the median PFS was 6.0 months (95% CI, 2.3-10.4), and the median overall survival was 22.6 months (95% CI, 9.8-not estimable).
Mechanism of Action and Immune Response
BNT113 is an investigational mRNA cancer immunotherapy encoding the E6 and E7 proteins of HPV16, which are frequently found in HPV16-positive solid tumors. Upon administration, these proteins are processed and presented to the immune system, activating CD8-positive and CD4-positive T cells to attack HPV16-positive cancer cells.
The trial demonstrated evidence of immune activation. Among three patients who provided peripheral blood mononuclear cells in the biomarker cohort, vaccine-induced T-cell responses were observed in two patients (66.7%) against the E6 and E7 peptides of HPV16. The expansion of de novo and pre-existing T-cell receptor clonotypes was observed across all three patients following vaccination.
Two patients had E7 antigen-specific CD8-positive T cells appearing de novo that were detectable until the end of treatment. BNT113 also triggered an immune response, as evidenced by post-vaccination increases in serum levels of CXCL10, IFNα, IFNγ, IL-10, IL-6, and TNFα.
Safety Profile
The combination of BNT113 and pembrolizumab was well tolerated, with treatment-emergent adverse effects mostly grade 1 to 2. All patients treated with BNT113 experienced a treatment-emergent adverse event or treatment-related adverse event. A total of 53.3% of patients experienced grade 3 or higher TEAEs, including 13.3% with treatment-related TEAEs.
The most common any-grade TEAEs included pyrexia (60.0%), chills (60.0%), fatigue (53.3%), and nausea (33.3%). Grade 3 TEAEs included anemia in two patients (13.3%) and single instances of pyrexia, fatigue, decreased appetite, abdominal pain, and hypercalcemia.
Trial Design and Patient Population
The open-label, two-arm trial features Part A with an initial safety run-in phase and Part B as the randomized, pivotal phase. Among the 15 patients treated with at least one dose of BNT113, the median age was 66.0 years (range, 41-74), 100% were male, and 66.7% had an ECOG performance status of 0. Most patients had either metastatic (40.0%) or unresectable recurrent disease (40.0%), had received prior platinum-based chemotherapy (73.3%), and had a primary site of disease in the oropharynx (86.7%).
Addressing Unmet Medical Need
The FDA fast track designation recognizes BNT113's potential to address a significant unmet medical need. There are currently no HPV-targeted treatments approved for patients with HPV16-positive HNSCC. The fast track process is designed to facilitate development and expedite review of new drugs intended to treat serious conditions with unmet medical needs.
Lead author Nabil F. Saba, MD, FACP, professor and vice chair for Quality and Safety at the Department of Hematology and Medical Oncology at Emory University School of Medicine, noted that the analysis confirmed the combination was well tolerated and that BNT113 triggered measurable immune responses.